Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Top Cited Papers
- 1 April 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 19 (4), 976-987
- https://doi.org/10.1158/1535-7163.mct-19-0873
Abstract
HER2 is a transmembrane tyrosine kinase receptor that mediates cell growth, differentiation, and survival. HER2 is overexpressed in approximately 20% of breast cancers and in subsets of gastric, colorectal, and esophageal cancers. Both antibody and small-molecule drugs that target HER2 and block its tyrosine kinase activity are effective in treating HER2-driven cancers. In this article, we describe the preclinical properties of tucatinib, an orally available, reversible HER2-targeted small-molecule tyrosine kinase inhibitor. In both biochemical and cell signaling experiments, tucatinib inhibits HER2 kinase activity with single-digit nanomolar potency and provides exceptional selectivity for HER2 compared with the related receptor tyrosine kinase EGFR, with a >1,000-fold enhancement in potency for HER2 in cell signaling assays. Tucatinib potently inhibits signal transduction downstream of HER2 and HER3 through the MAPK and PI3K/AKT pathways and is selectively cytotoxic in HER2-amplified breast cancer cell lines in vitro. In vivo, tucatinib is active in multiple HER2+ tumor models as a single agent and shows enhanced antitumor activity in combination with trastuzumab or docetaxel, resulting in improved rates of partial and complete tumor regression. These preclinical data, taken together with the phase-I tucatinib clinical trial results demonstrating preliminary safety and activity, establish the unique pharmacologic properties of tucatinib and underscore the rationale for investigating its utility in HER2+ cancers. Graphical Abstract: http://mct.aacrjournals.org/content/molcanther/19/4/976/F1.large.jpg.Keywords
Other Versions
Funding Information
- Seattle Genetics
- Seattle Genetics
This publication has 44 references indexed in Scilit:
- Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast CancerInternational Journal of Breast Cancer, 2012
- Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 HomodimersCancer Research, 2011
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylationProceedings of the National Academy of Sciences of the United States of America, 2010
- HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005Breast Cancer Research, 2009
- Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common CancersJournal of Oncology, 2009
- A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast CancerClinical Cancer Research, 2008
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancerThe Journal of Pathology, 2003
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987